Aquestive Therapeutics, Inc. (AQST) CEO Keith Kendall on Q3 2021 Results - Earnings Call TranscriptSeeking Alpha • 11/03/21
Aquestive Therapeutics Reports Third Quarter 2021 Financial Results, Provides Business Update and Improves Full Year GuidanceGlobeNewsWire • 11/02/21
Aquestive Therapeutics Reports Positive Topline Data from Phase 1 Pharmacokinetic Trial of AQST-109 (epinephrine prodrug sublingual film) Supporting its Development as an Oral Alternative to Epinephrine Autoinjectors for the Emergency Treatment of AllergiGlobeNewsWire • 10/25/21
Aquestive Therapeutics to Report Third Quarter 2021 Financial Results and Recent Business Highlights on November 2 and Host Conference Call on November 3 at 8:00 a.m. ETGlobeNewsWire • 10/14/21
Aquestive Therapeutics Reaches Agreement to Extend Principal Payments Due Under Credit Facility to March 30, 2023 and Receives Bridge Waiver of Principal Debt Payment in Advance of Concluding Formal AgreementGlobeNewsWire • 10/06/21
Aquestive Therapeutics to Participate in 12th Annual Wedbush PacGrow Healthcare Virtual ConferenceGlobeNewsWire • 08/06/21
Aquestive Therapeutics' (AQST) CEO Keith Kendall on Q2 2021 Results - Earnings Call TranscriptSeeking Alpha • 08/04/21
Aquestive Therapeutics Reports Second Quarter 2021 Financial Results, Provides Business Update and Raises Full Year Revenue GuidanceGlobeNewsWire • 08/03/21
Earnings Preview: Aquestive Therapeutics (AQST) Q2 Earnings Expected to DeclineZacks Investment Research • 07/27/21
Aquestive Therapeutics Announces FDA Acceptance of New Drug Application (NDA) Resubmission for Libervant™ (diazepam) Buccal FilmGlobeNewsWire • 07/19/21
Aquestive Therapeutics Resubmits New Drug Application for Libervant™ (diazepam) Buccal FilmGlobeNewsWire • 06/24/21
Aquestive Therapeutics Announces Leadership Transition of Chief Financial OfficerGlobeNewsWire • 06/21/21
Aquestive Therapeutics to Participate in JMP Securities and BMO Capital Market Investor ConferencesGlobeNewsWire • 06/09/21
Aquestive Therapeutics to Participate in 2021 RBC Capital Markets Global Healthcare ConferenceGlobeNewsWire • 05/11/21
Aquestive Therapeutics, Inc. (AQST) CEO Keith Kendall on Q1 2021 Results - Earnings Call TranscriptSeeking Alpha • 05/05/21
Aquestive Therapeutics Reports First Quarter 2021 Financial Results and Provides Business UpdateGlobeNewsWire • 05/04/21
DEADLINE TODAY: The Schall Law Firm Reminds Investors of Class Action Lawsuit Against Aquestive Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the FirmNewsfile Corp • 04/30/21
AQST Final Deadline: Bronstein, Gewirtz & Grossman, LLC Reminds Aquestive Therapeutics, Inc. Investors of Class Action and Lead Plaintiff Deadline: April 30, 2021Business Wire • 04/30/21
AQST Final Deadline Today: Rosen, Trusted National Trial Counsel, Encourages Aquestive Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important April 30 Deadline in Securities Class Action - AQSTNewsfile Corp • 04/30/21
AQST IMPORTANT DEADLINE FRIDAY: ROSEN, A LEADING LAW FIRM, Encourages Aquestive Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important April 30 Deadline in Securities Class Action - AQSTPRNewsWire • 04/29/21
DEADLINE TOMORROW: The Schall Law Firm Reminds Investors of Class Action Lawsuit Against Aquestive Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the FirmNewsfile Corp • 04/29/21
APRIL 30, 2021 AQST INVESTOR DEADLINE: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion In a Securities Class Action Against Aquestive Therapeutics, Inc.Newsfile Corp • 04/29/21